P 03. Efficacy of Shuganyiyang Capsules in the treatment of NIH category IIIA prostatitis and concomitant erectile dysfunction

Objective: To evaluate the effect of Shuganyiyang Capsules in the treatment of NIH category III A prostatitis with erectile dysfunction (ED).

Methods: Fifty cases diagnosed to have NIH category III A prostatitis with ED were randomized into Shuganyiyang Capsules group (group A, n=35) and control group (group B, n=15). In group A, NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) score was 25.4±9.3 and international index of Erectile Function-5 (IIEF-5) score was 12.2±3.3; Fluoroquinolones were used for 2 weeks and antagonist of α1-adrenoceptors and Non steroidal anti-inflammatory drugs were used for 4 weeks at the same time, then Shuganyiyang Capsules was added for 4 weeks. In group B, NIH-CPSI score was 25.7±9.0 and IIEF-5 score was 12.9±3.5; antagonist of α1-adrenoceptors and non steroidal antiinflammatory drugs were used for 8 weeks. All the cases were evaluated with IIEF-5 and NIH-CPSI at the 4th and 8th weeks after treatment respectively.

Results: At the end of the 4th week, NIH-CPSI score was 14.2±4.4 in group A and 13.5±5.1 in group B, which were significantly decreased compared with pre-treatment in both groups (P<0.01 for both); but there was no statistically significant difference between the 2 groups (P>0.05). IIEF-5 score was 16.3±4.2 in group A and 17.0±4.2 in group B, which were significantly increased compared with pre-treatment in both groups (P<0.01 for both); but there was no statistically significant difference between the 2 groups (P>0.05).The change of scores of NIH-CPSI was not correlated with that of IIEF-5. At the end of 8th week, NIH-CPSI score was 10.3±3.7 and IIEF-5 score was 20.8±4.4 in group A, which were significantly different from those at the end of 4th week (P<0.01 for both). NIH-CPSI score was 13.9±4.6 and IIEF-5 score was 16.1±4.8 in group B, which were not significantly different from those at the end of 4th week (P>0.05 for both). There were significant differences of NIH-CPSI and IIEF-5 scores between the 2 groups (P<0.01 for both). The change of NIH-CPSI score was negatively correlated with that of IIEF-5 in group A (r=–0.95, P<0.01).

Conclusions: For patients with NIH category III A prostatitis with ED, Shuganyiyang Capsules can effectively improve erectile function as well as decrease the NIH-CPSI score, thus in favor of covering from NIH category III A prostatitis.